Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears [Yahoo! Finance]
Jade Biosciences, Inc. (JBIO)
Company Research
Source: Yahoo! Finance
JADE101 (anti-APRIL) : A Phase 1 healthy-volunteer readout is expected in the first half of the year, and Jade says JADE101 is a femtomolar APRIL binder (claimed 750x potency vs. sibeprenlimab) with a YTE half-life extension aiming for subcutaneous dosing no more frequent than every eight weeks to drive deep, durable APRIL/IgA reductions. JADE201 (anti-BAFF-R) : First-in-human dosing is planned in Q2 in rheumatoid arthritis (as a surrogate for healthy-volunteer testing) with data expected in 2027; the program is designed to mimic ianalumab pharmacology but add half-life extension and will be evaluated across many potential indications where B-cell depletion is used. Financial runway : Jade ended 2025 with $336 million in cash, which management says should fund the company into the first half of 2028 and cover the near-term clinical milestones. Interested in Jade Biosciences, Inc.? Here are five stocks we like better. Jade Biosciences (NASDAQ:JBIO) outlined its strategy and ne
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Jade Biosciences to Participate in Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences to Participate in Upcoming ConferencesGlobeNewswire
- H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences (NASDAQ:JBIO) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- JBIO's page on the SEC website